Clinical

Dataset Information

0

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient


ABSTRACT: This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.

DISEASE(S): Metastatic Colorectal Cancer,Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients,Colorectal Neoplasms,Metastatic Colon Cancer,Pazienti Con Carcinoma Colorettale Metastatico Non Resecabile Kras Wild-type

PROVIDER: 2178666 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| 2228220 | ecrin-mdr-crc
2014-04-01 | E-GEOD-56386 | biostudies-arrayexpress
2021-06-14 | GSE141861 | GEO
2021-05-21 | GSE140973 | GEO
2014-04-01 | GSE56386 | GEO
| 2312043 | ecrin-mdr-crc
| 2630948 | ecrin-mdr-crc
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
| 2155383 | ecrin-mdr-crc